Pub Date : 2023-03-14DOI: 10.1007/s40495-023-00314-2
Shafkeen Siddiqui, M. Khushtar, A. Zafar, S. M. Hasan, M. Arshad, M. Ahmad, Mohd. Kashif, Mohammad Mujahid
{"title":"Mechanism-Based Physiological Effects of Piperine: A Review","authors":"Shafkeen Siddiqui, M. Khushtar, A. Zafar, S. M. Hasan, M. Arshad, M. Ahmad, Mohd. Kashif, Mohammad Mujahid","doi":"10.1007/s40495-023-00314-2","DOIUrl":"https://doi.org/10.1007/s40495-023-00314-2","url":null,"abstract":"","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"9 1","pages":"117 - 127"},"PeriodicalIF":0.0,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46138029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-13DOI: 10.1007/s40495-022-00311-x
Gurlovleen Kaur, Ranjeeta Bhari, Kuldeep Kumar
{"title":"Novel and Green Method for Synthesis of Fluorescent ZnS Quantum Dots from Latex of Plant Calotropis gigantea","authors":"Gurlovleen Kaur, Ranjeeta Bhari, Kuldeep Kumar","doi":"10.1007/s40495-022-00311-x","DOIUrl":"https://doi.org/10.1007/s40495-022-00311-x","url":null,"abstract":"","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"9 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2023-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43360452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-09DOI: 10.1007/s40495-022-00310-y
Savanna San Filippo, Marshall Yuan, E. Gu, Sabiyah Siddiqui, Savan Patel
{"title":"Utilization of Drug Decision Support Strategies Including Drug Characteristics to Reduce the Risk of Iatrogenesis in Advanced Age","authors":"Savanna San Filippo, Marshall Yuan, E. Gu, Sabiyah Siddiqui, Savan Patel","doi":"10.1007/s40495-022-00310-y","DOIUrl":"https://doi.org/10.1007/s40495-022-00310-y","url":null,"abstract":"","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"9 1","pages":"32-42"},"PeriodicalIF":0.0,"publicationDate":"2023-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48225671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1007/s40495-023-00312-4
Vakada Lakshmi Mounika, V Udaya Kumar, Sameer Dhingra, V Ravichandiran, Krishna Pandey, Vipan Kumar Parihar, Krishna Murti
The outbreak of the COVID-19 propagates, pressurizing the healthcare system by emphasizing and worsening the inequities. While many vaccines have shown excellent efficacy in protecting the general public from the COVID-19 infection, the efficacy of these vaccines for people living with HIV (PLHIV), especially those having a different range of CD4 + T-cell, has yet to be thoroughly investigated. Few studies have uncovered the escalated infection and death rates due to the COVID-19 infection in individuals with low CD4 + T-cells. Additionally, PLHIV has a low CD4 + count; furthermore, specific CD4 + T cells for coronavirus have a vigorous Th1 role and are related to the protective antibody responses. Follicular helper T cells (TFH) are vulnerable to HIV and virus-specific CD4 & CD8 T-cells which are essential for viral infection clearance and defective immune responses which further contributes to the development of illness. The specific CD8 & CD4 + T-cell reaction to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) was identified in almost all COVID-19 recovered individuals, which is related to the size of antibodies of immunoglobulin G. It has previously been demonstrated that PLHIV has decreased responses to certain vaccines and that these responses are reliant on CD4 + T-cell levels. COVID-19 vaccines will likely have a lower response or limited effect, in PLHIV having low CD4 + T-cells.
{"title":"CD4 + Count: a Variable to Be Considered to Prioritize COVID-19 Vaccination in PLHIV.","authors":"Vakada Lakshmi Mounika, V Udaya Kumar, Sameer Dhingra, V Ravichandiran, Krishna Pandey, Vipan Kumar Parihar, Krishna Murti","doi":"10.1007/s40495-023-00312-4","DOIUrl":"https://doi.org/10.1007/s40495-023-00312-4","url":null,"abstract":"<p><p>The outbreak of the COVID-19 propagates, pressurizing the healthcare system by emphasizing and worsening the inequities. While many vaccines have shown excellent efficacy in protecting the general public from the COVID-19 infection, the efficacy of these vaccines for people living with HIV (PLHIV), especially those having a different range of CD4 + T-cell, has yet to be thoroughly investigated. Few studies have uncovered the escalated infection and death rates due to the COVID-19 infection in individuals with low CD4 + T-cells. Additionally, PLHIV has a low CD4 + count; furthermore, specific CD4 + T cells for coronavirus have a vigorous Th1 role and are related to the protective antibody responses. Follicular helper T cells (TFH) are vulnerable to HIV and virus-specific CD4 & CD8 T-cells which are essential for viral infection clearance and defective immune responses which further contributes to the development of illness. The specific CD8 & CD4 + T-cell reaction to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) was identified in almost all COVID-19 recovered individuals, which is related to the size of antibodies of immunoglobulin G. It has previously been demonstrated that PLHIV has decreased responses to certain vaccines and that these responses are reliant on CD4 + T-cell levels. COVID-19 vaccines will likely have a lower response or limited effect, in PLHIV having low CD4 + T-cells.</p>","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"9 2","pages":"90-97"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9082646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1007/s40495-023-00318-y
Samriddhi Ranjan, Kanupriya Vashishth, Katrin Sak, Hardeep Singh Tuli
The world recently witnessed the emergence of new epidemic outbreaks like COVID-19 and mpox. The 2022 outbreak of mpox amid COVID-19 presents an intricate situation and requires strategies to combat the status quo. Some of the challenges to controlling an epidemic include present knowledge of the disease, available treatment options, appropriate health infrastructures facilities, current scientific methods, operations concepts, availability of technical staff, financial funds, and lastly international policies to control an epidemic state. These insufficiencies often hinder the control of disease spread and jeopardize the health of countless people. Also, disease outbreaks often put a huge burden on the developing economies. These countries are the worst affected and are immensely dependent on assistance provided from the larger economies to control such outbreaks. The first case of mpox was reported in the 1970s and several outbreaks were detected thereafter in the endemic areas eventually leading to the recent outbreak. Approximately, more than 80,000 individuals were infected, and 110 countries were affected by this outbreak. Yet, no definite vaccines and drugs are available to date. The lack of human clinical trials affected thousands of individuals in availing definite disease management. This paper focuses on the epidemiology of mpox, scientific concepts, and treatment options including future treatment modalities for mpox.
{"title":"The Emergence of Mpox: Epidemiology and Current Therapeutic Options.","authors":"Samriddhi Ranjan, Kanupriya Vashishth, Katrin Sak, Hardeep Singh Tuli","doi":"10.1007/s40495-023-00318-y","DOIUrl":"https://doi.org/10.1007/s40495-023-00318-y","url":null,"abstract":"<p><p>The world recently witnessed the emergence of new epidemic outbreaks like COVID-19 and mpox. The 2022 outbreak of mpox amid COVID-19 presents an intricate situation and requires strategies to combat the status quo. Some of the challenges to controlling an epidemic include present knowledge of the disease, available treatment options, appropriate health infrastructures facilities, current scientific methods, operations concepts, availability of technical staff, financial funds, and lastly international policies to control an epidemic state. These insufficiencies often hinder the control of disease spread and jeopardize the health of countless people. Also, disease outbreaks often put a huge burden on the developing economies. These countries are the worst affected and are immensely dependent on assistance provided from the larger economies to control such outbreaks. The first case of mpox was reported in the 1970s and several outbreaks were detected thereafter in the endemic areas eventually leading to the recent outbreak. Approximately, more than 80,000 individuals were infected, and 110 countries were affected by this outbreak. Yet, no definite vaccines and drugs are available to date. The lack of human clinical trials affected thousands of individuals in availing definite disease management. This paper focuses on the epidemiology of mpox, scientific concepts, and treatment options including future treatment modalities for mpox.</p>","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"9 3","pages":"144-153"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9520486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-31DOI: 10.1007/s40495-022-00305-9
Jiahui Liu, Xinhang Li, Yulin Zhu, R. Ge
{"title":"Molecular Mechanisms of Bismuth-containing Drugs Against Helicobacter pylori: a Further Update","authors":"Jiahui Liu, Xinhang Li, Yulin Zhu, R. Ge","doi":"10.1007/s40495-022-00305-9","DOIUrl":"https://doi.org/10.1007/s40495-022-00305-9","url":null,"abstract":"","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"9 1","pages":"59-65"},"PeriodicalIF":0.0,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47886626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-31DOI: 10.1007/s40495-022-00309-5
D. Ağagündüz, Ö. Cemali, E. Çelik
{"title":"Interaction Between Natural Products and Gut Microbiota","authors":"D. Ağagündüz, Ö. Cemali, E. Çelik","doi":"10.1007/s40495-022-00309-5","DOIUrl":"https://doi.org/10.1007/s40495-022-00309-5","url":null,"abstract":"","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"9 1","pages":"7-31"},"PeriodicalIF":0.0,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46007398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-02DOI: 10.1007/s40495-022-00308-6
Shubham Adhikary, M. Duggal, Saraswathy Nagendran, M. Chintamaneni, H. Tuli, Ginpreet Kaur
{"title":"Correction to: Lefamulin: a New Hope in the Field of Community-Acquired Bacterial Pneumonia","authors":"Shubham Adhikary, M. Duggal, Saraswathy Nagendran, M. Chintamaneni, H. Tuli, Ginpreet Kaur","doi":"10.1007/s40495-022-00308-6","DOIUrl":"https://doi.org/10.1007/s40495-022-00308-6","url":null,"abstract":"","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"8 1","pages":"464 - 466"},"PeriodicalIF":0.0,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42648894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号